Novel targets for HIV-1: Tat-TAR interactions
Award amount
$140,000Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PTC THERAPEUTICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LH7QEHP9V7W1
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Mechanism of nonsense mutation suppression therapy
- Development of an inhibitor of VEGF expression
- A Novel HIV-1 Latency System for Drug Discovery
- Developing antiviral agents that inhibit HCV translation
- Novel Approaches to Identify Anti-Angiogenesis Drugs
Research funding history
13 SBIR/STTR records share this UEI (2000–2006). Reported award amounts total $5,224,297. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services